Drug intelligence / Profile preview

DKF-310

Development stage: Phase 1
Lead developer: Dongkook Pharmaceutical
Modality: Small Molecules
Administration: Intramuscular

Overview

DKF-310 is an intramuscular formulation of donepezil developed by Dongkook Pharmaceutical. Donepezil is a small molecule acetylcholinesterase inhibitor primarily used for the treatment of Alzheimer's disease. DKF-310 was evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers[1][2][3]. The development focuses on providing an alternative delivery method (intramuscular injection) for donepezil, which is typically administered orally.

Other names: DKF-310DKF310DKF 310

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on DKF-310.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DKF-310.

Explore the full profile